A Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children

Pfizer

Status and phase: Completed; Phase 2; Phase 1

Conditions: Neutropenia

Treatments: Drug: Voriconazole

Study type: Interventional

Funder types: Industry

Identifiers

NCT00174473

A1501037

Details and patient eligibility

About

This is a study to investigate the pharmacokinetics, safety and tolerability of several doses of voriconazole, intravenous and oral suspension formulations, in children

Enrollment: 49 patients

Sex: All

Ages: 2 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Children who require a systemic antifungal agent for the prevention of systemic fungal infection

Exclusion criteria

• Children who are receiving medications which cannot be taken concomitantly with voriconazole.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)